diallyl trisulfide has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, X; Liu, Q; Pang, H; Wang, C; Wang, L; Ye, J; Zhang, J; Zhou, X | 1 |
| Bhushan, S; Bir, SC; Calvert, JW; Kevil, CG; Kondo, K; Lefer, DJ; Murohara, T; Polhemus, D | 1 |
2 other study(ies) available for diallyl trisulfide and Cirrhosis
| Article | Year |
|---|---|
Diallyl trisulfide plays an antifibrotic role by inhibiting the expression of Bcl-2 in hepatic stellate cells.
Topics: Allyl Compounds; Apoptosis; bcl-2-Associated X Protein; Fibrosis; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Sulfides | 2022 |
Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis.
Topics: Allyl Compounds; Angiostatins; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Hydrogen Sulfide; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Myocardium; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Sulfides; Time Factors; Ultrasonography; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2013 |